Showing 781-790 of 1601 results for "".
- Practical Dermatology Names Dr. Lisa Swanson Associate Medical Editorhttps://practicaldermatology.com/news/practical-dermatology-names-dr-lisa-swanson-associate-medical-editor/2470863/Elizabeth (Lisa) Swanson, MD, FAAD, has accepted the position of Associate Medical Editor of Practical Dermatology, the journal announced. In this capacity, Dr. Swanson will work closely with Chief Medical Editor Neal Bhatia, MD, FAAD, to provide direction for Practical Dermat
- Skin Cancer Foundation Names New Executive Directorhttps://practicaldermatology.com/news/skin-cancer-foundation-names-new-executive-director/2470856/The Skin Cancer Foundation (SCF), a national nonprofit organization that is committed to decreasing the incidence and mortality of the world’s most common cancer through public education, announced that it has appointed Becky Kamowitz to the role of executive director. Kamowitz has worked
- Knight Dermatology Institute Partners With Forefront Dermatologyhttps://practicaldermatology.com/news/knight-dermatology-institute-partners-forefront-dermatology/2470808/Knight Dermatology Institute (KDI) and Forefront Dermatology have formed a partnership, Physician Growth Partners (PGP) announced in a press release. Based in Orlando, Florida, KDI is a medically and surgically driven practice with a core focus on skin cancer detection, prevention, and tre
- Report: Regenerative Aesthetics Exosome Market Poised for Growth Through 2031https://practicaldermatology.com/news/report-regenerative-aesthetics-exosome-market-poised-355-cagr-through-2031/2470805/The global regenerative aesthetics exosome products market is projected to experience a compound annual growth rate (CAGR) of 35.5% from 2024 to 2031, according to a report from InsightAce Analytic. Exosome-based therapies with applications in skin rejuvenation, hair restoration, scar redu
- Castle Biosciences' Test Identifies AD Patients Likely to Achieve EASI90https://practicaldermatology.com/news/castle-biosciences-test-identifies-ad-patients-likely-achieve-easi90/2470795/Castle Biosciences has announced its investigational gene expression profile test for atopic dermatitis (AD) may identify patients likely to achieve a 90% or greater reduction in Eczema Area and Severity Index (EASI) scores within three months of targeted therapy initiation. Currently, ov
- National Rosacea Society Introduces Informational Postcardhttps://practicaldermatology.com/news/national-rosacea-society-introduces-informational-postcard/2470763/The National Rosacea Society (NRS) announced today that it has released a new educational postcard to raise awareness about rosacea, a chronic skin condition affecting over 16 million Americans. Titled “Rosacea: A Common Disease, Uncommonly Treated,” the resource is designed for d
- Arcutis Submits sNDA for Roflumilast for Children 2 to 5 With ADhttps://practicaldermatology.com/news/arcutis-submits-snda-roflumilast-children-2-5-ad/2470667/Arcutis Biotherapeutics, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for roflumilast (ZORYVE) cream 0.05%, a once-daily, next-generation phosphodiesterase 4 (PDE4) inhibitor, for the topical treatment of mild-to-moderate
- AARS Scholar Grant to Be Used for Antibiotics Researchhttps://practicaldermatology.com/news/aars-scholar-grant-be-used-antibiotics-research/2470665/The American Acne and Rosacea Society (AARS) announced that the 2024 AARS Clinical Research Scholar Grant has been provided to Jean McGee, MD, PhD, of the Department of Dermatology at Brigham and Women’s Hospital in Boston. Additionally, AARS Clinical Research Grants are being provided to
- FDA Approves Tapinarof Cream, 1%, for ADhttps://practicaldermatology.com/news/fda-approves-tapinarof-cream-1-ad/2470664/The US Food and Drug Administration (FDA) approved tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older, Organon announced. Organon received the FDA appr
- Veradermics Gets New Financing for AGA/PHL Candidatehttps://practicaldermatology.com/news/veradermics-gets-new-financing-agaphl-candidate/2468761/Veradermics announced the closing of a $75 million Series B financing, proceeds of which will be used to fund the ongoing clinical development of the company’s lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL). "The initiation of our pivota